Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,114 public trials 586 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Recruiting

A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07493135

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing GoBroad Boren Hospital Beijing, China
  • The second affiliated hospital of Chongqing medical university Chongqing, China
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China
  • Zhengzhou Yihe Hospital Zhengzhou, China
View Trial Details
Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Yale New Haven Hospital-Smilow Cancer Center New Haven, Connecticut, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 22 locations
View Trial Details
Recruiting

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

NCT06561347

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Colorado Blood Cancer Institute (CBCI) Denver, Colorado, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Recruiting

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

NCT05272826

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • NL Health Services St. John's, Newfoundland and Labrador, Canada
  • QEII Health Science Centre Halifax, Nova Scotia, Canada
  • London Health Sciences Centre London, Ontario, Canada
View Trial Details
Recruiting

Elranatamab in R/R Multiple Myeloma

NCT06138275

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Beth-Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335

Conditions
Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +22 more
Locations
  • City of Hope Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 29 locations
View Trial Details
Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT06375044

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Mayo Clinic Florida Jacksonville, Florida, United States
  • Dana Farber Cancer institution Boston, Massachusetts, United States
  • Mayo Clinic Rochester Rochester, Minnesota, United States
View all 16 locations
View Trial Details
Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Aalborg Sygehus Syd Aalborg, Denmark
  • Aarhus Universitetshospital Aarhus N, Denmark
  • Rigshospitalet Copenhagen, Denmark
  • Odense University Hospital Odense, Denmark
View all 68 locations
View Trial Details

Related conditions